HCW Biologics HCWB

HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases driven by chronic inflammation. The company focuses on the dual pathways of persistent immune cell activation and senescent cell accumulation that underlie chronic inflammatory conditions. It uses its proprietary TOBI platform, which employs a tissue factor scaffold to combine multiple cytokines, chemokines, ligands receptors and single chain antibodies into multifunctional proteins, and its TRBC platform, which uses the T cell receptor beta chain constant region as a scaffold to build chimeric polypeptides that engage immune signaling pathways. Through these platforms HCW Biologics has created over 50 distinct molecules that can be administered by subcutaneous injection or used in adoptive cell therapy approaches. Its pipeline includes the clinical-stage candidate HCW9302, an interleukin 2 fusion protein designed to expand regulatory T cells for autoimmune indications such as alopecia areata, and preclinical candidates such as HCW11-018b, a tetra valent T cell engager aimed at solid tumours, and HCW11-040, a fusion of cytokines and pembrolizumab intended to enhance anti tumour activity while avoiding cytokine storm. The company also commercializes reagents HCW9201 and HCW9206, which are used to improve the manufacturing of CAR T and natural killer cell therapies.

The company generates revenue primarily through licensing agreements and associated payments. It has recognized $16.2 million from its license with Wugen, comprising upfront fees, milestone payments and royalties. It also received an upfront $3.5 million payment from TRimmune under an amended license agreement and is eligible for further milestone payments and double digit royalties on future product sales. In addition, HCW Biologics sells its commercial-ready reagents HCW9201 and HCW9206 to partners for use in CAR T and natural killer cell manufacturing, providing another stream of income. The company retains all other rights to HCW9206 outside of oncology indications and maintains the ability to out license those rights to additional parties.

The company operates in the competitive biopharmaceutical sector focused on immunotherapy, autoimmune disorders, cancer and senescence associated diseases. It faces competition from large pharmaceutical firms such as Merck & Co., Bristol Myers Squibb, Pfizer, Novartis, Roche and Johnson & Johnson, as well as specialized biotechs including Amgen, Gilead, Kite Pharma, Bluebird Bio and others developing chimeric antigen receptor T cell therapies, interleukin 2 based therapies and checkpoint inhibitors. HCW Biologics differentiates itself through its proprietary TOBI and TRBC platforms, a broad patent portfolio with protection extending to 2041, and deep expertise in protein engineering that enables the creation of multifunctional molecules with improved safety profiles and manufacturability. The company’s strategy targets indications with limited or no FDA approved treatments, leveraging its scientific knowledge of inflammaging to develop first in class candidates that address unmet medical needs in areas such as autoimmune dermatology, neurodegenerative disorders and perinatal lung disease.

The company’s customers include its licensing partners Wugen and Beijing Trimmune Biotech Co., Ltd., which develop and commercialize its reagents and product candidates. It also collaborates with research institutions such as The Ohio State University Wexner Medical Center and James A. Haley Veterans Hospital for clinical trials of HCW9302 in alopecia areata. Additionally, HCW Biologics works with contract manufacturers like EirGenix to produce clinical grade material for its product candidates under cGMP standards. These relationships provide the company with access to manufacturing expertise, clinical trial sites and potential downstream partners for future commercialization.